PRTA
Prothena Corporation plcNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.93
P/S
55.81
EV/EBITDA
-1.42
DCF Value
$3.35
FCF Yield
-31.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
-208.6%
Operating Margin
-2247.5%
Net Margin
-2520.6%
ROE
-73.0%
ROA
-74.7%
ROIC
-75.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $21.0K | $-21.6M | $-0.40 |
| FY 2025 | $9.7M | $-244.1M | $-4.53 |
| Q3 2025 | $2.4M | $-36.5M | $-0.68 |
| Q2 2025 | $4.4M | $-125.8M | $-2.34 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
IE
Exchange
NASDAQ
Beta
-0.33
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.